NADPH Cytochrome P450 Oxidoreductase

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
(New page: {{STRUCTURE_3es9| PDB=3es9 | SCENE=Sandbox_177/Jmol3es9/1 }} == '''NADPH-cytochrome P450 oxidoreductase''' == ==='''General Information'''=== ---- Horecker first identified this protein i...)
Current revision (14:34, 4 November 2019) (edit) (undo)
 
(6 intermediate revisions not shown.)
Line 1: Line 1:
-
{{STRUCTURE_3es9| PDB=3es9 | SCENE=Sandbox_177/Jmol3es9/1 }}
+
<StructureSection load='3es9' size='350' side='right' scene='' caption='NADPH cytochrome P450 oxidoreductase complex with flavin mononucleotide, FAD and NADP, (PDB Code [[3es9]])'>
== '''NADPH-cytochrome P450 oxidoreductase''' ==
== '''NADPH-cytochrome P450 oxidoreductase''' ==
Line 12: Line 12:
==='''Structure'''===
==='''Structure'''===
----
----
-
<applet load='3es9' size='275' color='black' frame='true' align='left' scene='Sandbox_177/Cyporplain/2' caption='Figure 1: Highlighting the chains and associated ligands of CYPOR'/>
+
 
<scene name='Sandbox_177/Cyporplain/2'>CYPOR</scene> is a complex, multidomain protein composed of three asymmetric chains, (<scene name='Sandbox_177/Cyporchaina/2'>A</scene>, <scene name='Sandbox_177/Cyporchainb/1'>B</scene>, <scene name='Sandbox_177/Cyporchainc/1'>C</scene>). It also has three different types of associated ligands; one <scene name='Sandbox_177/Cyporfmn/2'>FMN</scene>, three <scene name='Sandbox_177/Cyporfad/2'>FAD</scene> and two <scene name='Sandbox_177/Cypornadph/2'>NADPH</scene> (Fig 1).<ref name="5TSON"/> The three associated binding domains for these ligand types, a connecting domain and a transmembrane anchor make up the important structural elements of CYPOR (Fig 2).
<scene name='Sandbox_177/Cyporplain/2'>CYPOR</scene> is a complex, multidomain protein composed of three asymmetric chains, (<scene name='Sandbox_177/Cyporchaina/2'>A</scene>, <scene name='Sandbox_177/Cyporchainb/1'>B</scene>, <scene name='Sandbox_177/Cyporchainc/1'>C</scene>). It also has three different types of associated ligands; one <scene name='Sandbox_177/Cyporfmn/2'>FMN</scene>, three <scene name='Sandbox_177/Cyporfad/2'>FAD</scene> and two <scene name='Sandbox_177/Cypornadph/2'>NADPH</scene> (Fig 1).<ref name="5TSON"/> The three associated binding domains for these ligand types, a connecting domain and a transmembrane anchor make up the important structural elements of CYPOR (Fig 2).
Line 22: Line 22:
----
----
[[Image:CPR chargepair.gif|thumb|right|300px|Figure 2: Electrostatic charge pairing between Cyt P450 and the FMN binding domain induces the interaction between CYPOR and Cyt P450.]]
[[Image:CPR chargepair.gif|thumb|right|300px|Figure 2: Electrostatic charge pairing between Cyt P450 and the FMN binding domain induces the interaction between CYPOR and Cyt P450.]]
 +
{{Clear}}
''In vivo'' CYPOR is believe to alternate between a one and a three electron reduced form. While the 1 electron form is fairly stable, forming a neutral blue semiquinone, it is the hydroquinone, or 3 electron form, that is able to donate electrons to the desired redox partners.
''In vivo'' CYPOR is believe to alternate between a one and a three electron reduced form. While the 1 electron form is fairly stable, forming a neutral blue semiquinone, it is the hydroquinone, or 3 electron form, that is able to donate electrons to the desired redox partners.
Line 37: Line 38:
'''Embryology & Development''' - CYPOR is believed to play a key role in the spatial and temporal expression of various signaling factors that are key in establishing correct embryogenesis and development pathways.<ref name="9TSON">PMID:11742006</ref> Studies with mice have shown that CYPOR is critical for mice embryos to progress into and past mid-gestation, as embryos lacking both CYPOR alleles did not survive past day 13.5 of gestation. <ref name="9TSON"/> Even heterozygous mice were found to have a decreased survival rate after 2 weeks of gestation.<ref name="9TSON"/> In humans, while deficiencies in CYPOR are not necessarily lethal, they do have some severe side effects, including disordered steroidogenesis and Antley-Bixler syndrome (ABS).<ref name="10aTSON"/><ref name="10bTSON">PMID:16467261</ref> ABS is associated with urogenital defects (ie: ambiguous genitalia), cranial abnormalities (ie: brachycephaly) and skeletal defects (ie: bowed femurs, narrow ribcage and club feet), often due to disordered steroidogenesis.<ref name="10aTSON"/><ref name="10bTSON"/> Individuals with ABS and/or disordered steroidogenesis may have mutations in one or both alleles for CYPOR, although some cases are associated with mutations in another gene, fibroblast growth factor receptor 2 gene.<ref name="10bTSON"/><ref name="10aTSON"/>
'''Embryology & Development''' - CYPOR is believed to play a key role in the spatial and temporal expression of various signaling factors that are key in establishing correct embryogenesis and development pathways.<ref name="9TSON">PMID:11742006</ref> Studies with mice have shown that CYPOR is critical for mice embryos to progress into and past mid-gestation, as embryos lacking both CYPOR alleles did not survive past day 13.5 of gestation. <ref name="9TSON"/> Even heterozygous mice were found to have a decreased survival rate after 2 weeks of gestation.<ref name="9TSON"/> In humans, while deficiencies in CYPOR are not necessarily lethal, they do have some severe side effects, including disordered steroidogenesis and Antley-Bixler syndrome (ABS).<ref name="10aTSON"/><ref name="10bTSON">PMID:16467261</ref> ABS is associated with urogenital defects (ie: ambiguous genitalia), cranial abnormalities (ie: brachycephaly) and skeletal defects (ie: bowed femurs, narrow ribcage and club feet), often due to disordered steroidogenesis.<ref name="10aTSON"/><ref name="10bTSON"/> Individuals with ABS and/or disordered steroidogenesis may have mutations in one or both alleles for CYPOR, although some cases are associated with mutations in another gene, fibroblast growth factor receptor 2 gene.<ref name="10bTSON"/><ref name="10aTSON"/>
 +
 +
</StructureSection>
 +
==3D structures of NADPH-cytochrome P450 oxidoreductase==
 +
 +
[[NADPH-Cytochrome P450 Reductase]]
 +
 +
==Additional Resources==
 +
For additional information, see: [[Cancer]]
 +
<br />
==References==
==References==
<references/>
<references/>

Current revision

NADPH cytochrome P450 oxidoreductase complex with flavin mononucleotide, FAD and NADP, (PDB Code 3es9)

Drag the structure with the mouse to rotate

3D structures of NADPH-cytochrome P450 oxidoreductase

NADPH-Cytochrome P450 Reductase

Additional Resources

For additional information, see: Cancer

References

  1. Horecker BL. Triphosphopyridine nucleotide-cytochrome c reductase in liver. J Biol Chem 1950 Apr 1;183(2):593-605
  2. 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 2.11 2.12 2.13 2.14 2.15 2.16 2.17 2.18 2.19 2.20 2.21 2.22 2.23 2.24 2.25 Hamdane D, Xia C, Im SC, Zhang H, Kim JJ, Waskell L. Structure and function of an NADPH-cytochrome P450 oxidoreductase in an open conformation capable of reducing cytochrome P450. J Biol Chem. 2009 Apr 24;284(17):11374-84. Epub 2009 Jan 26. PMID:19171935 doi:10.1074/jbc.M807868200
  3. Phillips AH, Langdon RG. Hepatic triphosphopyridine nucleotide-cytochrome c reductase: Isolation, characterization, and kinetic studies. J Biol Chem 1962 Aug 1;237:2652-60
  4. 4.0 4.1 Smith GC, Tew DG, Wolf CR. Dissection of NADPH-cytochrome P450 oxidoreductase into distinct functional domains. Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8710-4. PMID:8078947
  5. Li HC, Liu D, Waxman DJ. Transcriptional induction of hepatic NADPH: cytochrome P450 oxidoreductase by thyroid hormone. Mol Pharmacol. 2001 May;59(5):987-95. PMID:11306680
  6. Waxman DJ, Morrissey JJ, Leblanc GA. Hypophysectomy differentially alters P-450 protein levels and enzyme activities in rat liver: pituitary control of hepatic NADPH cytochrome P-450 reductase. Mol Pharmacol. 1989 Apr;35(4):519-25. PMID:2495435
  7. Ram PA, Waxman DJ. Thyroid hormone stimulation of NADPH P450 reductase expression in liver and extrahepatic tissues. Regulation by multiple mechanisms. J Biol Chem. 1992 Feb 15;267(5):3294-301. PMID:1737785
  8. 8.0 8.1 8.2 8.3 Tomkova M, Marohnic CC, Baxova A, Martasek P. [Antley-Bixler syndrome or POR deficiency?] Cas Lek Cesk. 2008;147(5):261-5. PMID:18630181
  9. 9.0 9.1 9.2 9.3 Nadler SG, Strobel HW. Identification and characterization of an NADPH-cytochrome P450 reductase derived peptide involved in binding to cytochrome P450. Arch Biochem Biophys. 1991 Nov 1;290(2):277-84. PMID:1929397
  10. 10.0 10.1 10.2 10.3 Tamburini PP, Schenkman JB. Differences in the mechanism of functional interaction between NADPH-cytochrome P-450 reductase and its redox partners. Mol Pharmacol. 1986 Aug;30(2):178-85. PMID:3016501
  11. Hasemann CA, Kurumbail RG, Boddupalli SS, Peterson JA, Deisenhofer J. Structure and function of cytochromes P450: a comparative analysis of three crystal structures. Structure. 1995 Jan 15;3(1):41-62. PMID:7743131
  12. 12.0 12.1 Canessa M, Laski C, Falkner B. Red blood cell Na+ transport as a predictor of blood pressure response to Na+ load in young blacks and whites. Hypertension. 1990 Nov;16(5):508-14. PMID:2228151
  13. 13.0 13.1 13.2 Shen AL, O'Leary KA, Kasper CB. Association of multiple developmental defects and embryonic lethality with loss of microsomal NADPH-cytochrome P450 oxidoreductase. J Biol Chem. 2002 Feb 22;277(8):6536-41. Epub 2001 Dec 12. PMID:11742006 doi:10.1074/jbc.M111408200
  14. 14.0 14.1 14.2 Miller WL, Huang N, Pandey AV, Fluck CE, Agrawal V. P450 oxidoreductase deficiency: a new disorder of steroidogenesis. Ann N Y Acad Sci. 2005 Dec;1061:100-8. PMID:16467261 doi:1061/1/100
Personal tools